middle.news
How Opthea’s $340M Profit Fuels a Bold Pivot to Rare Lung Disease Therapy
8:24am on Monday 2nd of March, 2026 AEDT
•
Biotechnology
Read Story
How Opthea’s $340M Profit Fuels a Bold Pivot to Rare Lung Disease Therapy
8:24am on Monday 2nd of March, 2026 AEDT
Key Points
H1 2026 profit of A$339.9 million after DFA settlement reversal
Strategic pivot to develop OPT-302 targeting rare lung disease LAM
CEO transition with Chairman Jeremy Levin assuming leadership
Strong cash position supports self-funded early development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE